RecruitingPhase 4NCT06494072

Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP

Short Versus Standard of Care Antibiotic Duration for Hospitalized Children With Uncomplicated Community-acquired Pneumonia: a Non-inferiority, Randomized Controlled Trial.


Sponsor

Medical College of Wisconsin

Enrollment

236 participants

Start Date

Aug 22, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this open label, randomized, non-inferiority clinical trial is to compare the treatment success of a 5 day antibiotic course versus a standard antibiotic course (usually 7-14 days of antibiotics) in hospitalized children aged 3 months to 18 years, with uncomplicated community acquired pneumonia. The main questions it aims to answer are: * Does a 5 day course work as well as standard (longer) courses of antibiotics for treating community acquired pneumonia in children? * Does a 5 day course cause less antibiotic side effects compared to a standard (longer) course of antibiotics in children with community acquired pneumonia? Participants will * be randomly assigned to either receive 5 total days or a total duration decided by the treating physician * receive a brief follow up questionnaire regarding clinical symptoms, follow up care/antibiotics, and side effects via phone or email at days 5 and 14 from the start of antibiotics Researchers will compare the experimental group (receiving 5 days duration) with the control group (standard duration) to see if 5 days is as successful as a standard duration.


Eligibility

Min Age: 3 MonthsMax Age: 18 Years

Inclusion Criteria5

  • Children aged 3 months to \<18 years old
  • Hospitalized in either the acute care or the pediatric intensive care units
  • Clinically diagnosed with uncomplicated bacterial community acquired pneumonia (as determined by the treating physician)
  • Radiological findings suggestive of pneumonia (such as consolidation, lobar or interstitial infiltrates)
  • Achieved clinical stability within 72 hours from the first antibiotic dose (clinical stability includes being off supplemental oxygen/ventilatory support and temperature remaining \< 38 Celsius).

Exclusion Criteria16

  • Hemodynamic instability at any point during hospitalization that required inotropic support
  • Requirement of respiratory support \> 72 hours
  • Presence of a parapneumonic effusion \>10 mm on decubitus x-ray or greater than ¼ of hemithorax opacified on chest imaging
  • Need for chest tube placement
  • Extrapulmonary involvement (ie: another infection located outside of the lungs) except for otitis media if the planned treatment is ≤ 5 days
  • Pneumonia caused by known staphylococcus aureus identified from culture (blood, bronchoalveolar aspirate, tracheal aspirate, or pleural fluid)
  • Antibiotic course started \>72 hours after admission
  • Antibiotics used for \> 24 hours within the 2 weeks prior to admission
  • Chronic respiratory illness other than asthma or reactive airway disease
  • Immunocompromised patient (primary or secondary)
  • Primary physician refusal
  • Parent refusal
  • Non-English speakers
  • Pregnant or lactating female
  • Participant will become ≥ 18 years old at or before the time of day 14 follow up
  • Inability to adhere to follow up

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAmpicillin for Injection

Ampicillin is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.

DRUGCeftriaxone for Injection

Ceftriaxone is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.

DRUGAmoxicillin

Amoxicillin is an oral antibiotic commonly used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.

DRUGAmpicillin / Sulbactam Injection

Ampicillin/Sulbactam is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.

DRUGAmoxicillin-clavulanate

Amoxicillin-clavulanate is an oral antibiotic commonly used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.

DRUGClindamycin

Clindamycin is an antibiotic that can be given intravenously or orally that is sometimes used in the treatment of children hospitalized or discharged with community-acquired pneumonia.

DRUGCefprozil

Cefprozil is an oral antibiotic sometimes used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.

DRUGLevofloxacin

Levofloxacin is an antibiotic that can be given intravenously or orally that is sometimes used in the treatment of children hospitalized or discharged with community-acquired pneumonia.


Locations(1)

Childrens Wisconsin

Milwaukee, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06494072


Related Trials